first week of tirzepatide caused roughly half as many patients to stop treatment because gastrointestinal side effects as semaglutide. In the major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide First Week on Tirzepatide: What

FDA statement on enforcement priorities regarding compounded GLP-1 receptor agonist products [Press release]

Until stronger human lactation data is available, most experts advise prioritizing breastfeeding and recovery over GLP-1 use, regardless of dose size

In a statement, the clinic said it operates without the need for blood work or insurance, maintaining 100% FDA compliance as the medication is compounded in a registered FDA pharmacy

This stepwise approach is characteristic of FDA enforcement practice, and companies would be well-advised to treat these letters as genuine precursors to litigation

European Journal of Applied Physiology, 73, 434-439